A drug repurposing screen reveals dopamine signaling as a candidate therapeutic pathway for PIGA-CDG
By utilizing a *Drosophila* eye model to screen FDA/EMA-approved compounds, researchers identified that modulating dopamine signaling and cyclooxygenase pathways can rescue the small eye phenotype and alleviate neurological symptoms in PIGA-CDG, offering promising repurposed therapeutic candidates for this currently untreatable disorder.